Evaluating the cytotoxicity of flaxseed orbitides for potential cancer treatment. (2015)

• Record Type: Journal Article
• Authors: Okinyo-Owiti, Denis P.; Dong, Qiulin; Ling, Binbing; Jadhav, Pramodkumar D.; Bauer, Robert; Maley, Jason M.; Reaney, Martin J.T.; Yang, Jian; Sammynaiken, Ramaswami
• Is Part Of: Toxicology reports. Volume 2(2015)
• Page Start: 1014
• Page End: 1018
• Publication Date: 2015
• Subjects: Flaxseed linoorbitide -- Cytotoxicity -- Breast cancer -- Melanoma; Toxicology -- Periodicals; Clinical toxicology -- Periodicals; Drug-Related Side Effects and Adverse Reactions; Hazardous Substances; Poisoning; Toxicology; Electronic journals; Periodicals; Periodicals; 571.9505
• DOI: 10.1016/j.toxrep.2015.06.011
• Languages: English
• ISSNs: 2214-7500

Abstract

Abstract: Flaxseed as well as its oil component possess antitumor activities against different types of cancer and have been used by some patients as complementary and/or alternative medicine. Linoorbitides (LOBs) are one family of flaxseed compounds that has implications for anticancer and antioxidant activity. The cytotoxicity of [1-9-NαC]-linusorb-B3 (LOB3), [1-9-NαC]-linusorb-B2 (LOB2), [1-9-NαC], [1-Rs, Ss -MetO]-linusorb-B2 ([MetO]-LOB2) and [1-8-NαC], [1-Rs, Ss -MetO]-linusorb-B1 ([MetO]-LOB1) was measured against human breast cancer Sk-Br-3 and MCF7 cell lines and melanoma A375 cell line. Overall cytotoxicity is cell-type specific. It scales as the hydrophobicity and concentration of the LOBs with the most abundant LOB3 being the most cytotoxic. Oral administration of LOB3 as a potential therapeutic agent might not be applicable as a much too high and/or frequent dose would be required to achieve a serum concentration of 400–500 μg/mL due to bioavailability and pharmacokinetic factors. However, LOB3 may be suitable for topical treatment formulations or as a lead compound in developing anticancer LOB derivatives.